Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer

被引：0
|
作者：
Lee, F. [1 ]
Roach, M. [1 ]
Duong, L. [1 ]
Heywood, G. [1 ]
Parasher, G. [1 ]
Rasila, K. [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15180
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
    Tahara, Makoto
    Shirao, Kuniaki
    Boku, Narikazu
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Inaba, Yoshitaka
    Arai, Tatsuhiro
    Mizunuma, Nobuyuki
    Satoh, Taroh
    Takiuchi, Hiroya
    Nishina, Tomohiro
    Sakata, Yuh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 762 - 769
  • [22] Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Masi, Gianluca
    Vasile, Enrico
    Loupakis, Fotios
    Bursi, Simona
    Ricci, Sergio
    Petrini, Iacopo
    Fontana, Andrea
    Allegrini, Giacomo
    Falcone, Alfredo
    CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 7 - 14
  • [23] Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients
    Bajetta, E
    Beretta, E
    Di Bartolomeo, M
    Cortinovis, D
    Ferrario, E
    Dognini, G
    Toffolatti, L
    Buzzoni, R
    ONCOLOGY, 2004, 66 (02) : 132 - 137
  • [24] Cetuximab alone or in combination with irinotecan effective against irinotecan refractory colorectal cancer
    Lang, L
    GASTROENTEROLOGY, 2004, 127 (03) : 701 - 701
  • [25] Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
    Di Lauro, L.
    Nunziata, C.
    Arena, M. G.
    Foggi, P.
    Sperduti, I.
    Lopez, M.
    BRITISH JOURNAL OF CANCER, 2007, 97 (05) : 593 - 597
  • [26] Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
    L Di Lauro
    C Nunziata
    M G Arena
    P Foggi
    I Sperduti
    M Lopez
    British Journal of Cancer, 2007, 97 : 593 - 597
  • [27] Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS
    Hong, Yong Sang
    Kim, Hwa Jung
    Park, Seong Joon
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Jin Hong
    Kim, Jong Hoon
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Jin Cheon
    Baek, Ji Yeon
    Kim, Sun Young
    Kim, Tae Won
    CANCER SCIENCE, 2013, 104 (04) : 473 - 480
  • [28] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    Sobrero, Alberto F.
    Maurel, Joan
    Fehrenbacher, Louis
    Scheithauer, Werner
    Abubakr, Yousif A.
    Lutz, Manfred P.
    Vega-Villegas, M. Eugenia
    Eng, Cathy
    Steinhauer, Ernst U.
    Prausova, Jana
    Lenz, Heinz-Josef
    Borg, Christophe
    Middleton, Gary
    Kroening, Hendrik
    Luppi, Gabriele
    Kisker, Oliver
    Zubel, Angela
    Langer, Christiane
    Kopit, Justin
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2311 - 2319
  • [29] Cetuximab and irinotecan in patients with EGFR plus colorectal cancer refactory to oxaliplatin and irinotecan: A single institution experience
    Herrero, A
    Alonso, V
    Lao, J
    de Lobera, AR
    Pazo, R
    Martinez-Trufero, J
    Puertolas, T
    Calderero, V
    Artal, A
    Anton, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 302S - 302S
  • [30] Biweekly cetuximab and irinotecan for the treatment of refractory metastatic colorectal cancer
    Martín-Martorell, Paloma
    Rodriguez-Braun, Edith
    Perez-Fidalgo, Alejandro
    Chirivella, Isabel
    Insa, Amelia
    Cervantes, Andrés
    ANNALS OF ONCOLOGY, 2007, 18 : 168 - 168
12345